The development of new therapies is a highly structured and collaborative scientific process that requires significant time and investment to progress from molecular discovery to regulatory approval. This complex pathway was thoroughly analyzed during a recent educational seminar hosted by the European CMT Federation (ECMTF). The session was led by Marzena Nelken, EUPATI Fellow, representative of the Federation of Polish Patients, and expert at the Supreme Bioethical Committee in Poland.
The seminar highlighted how synergy among researchers, health institutions, and the patient community is a fundamental requirement. Patients are active co-creators from the earliest stages of study design, ensuring that research addresses real clinical needs and maintains strict ethical standards through tools like lay-language informed consent.
The Development Process: From Preclinical to Clinical Phases
Before a molecule can be tested in humans, it must pass rigorous preclinical screening to assess its safety profile. Only a small fraction of compounds advances to clinical trials, which are divided into four main phases regulated by international agencies such as the EMA and FDA:
- Phase 1 (Safety and Pharmacokinetics): Involves a very small group of participants, usually healthy volunteers, in highly controlled clinical settings. The primary goal is to measure safety, determine the maximum tolerated dose, and understand how the body processes the substance.
- Phase 2 (Preliminary Efficacy – Proof of Concept): The therapy is administered to a targeted group of patients affected by the condition (approximately 100-500 individuals). This phase gathers preliminary efficacy data and establishes the optimal dosage, often utilizing randomized, double-blind methodologies to ensure scientific objectivity.
- Phase 3 (Large-Scale Confirmation): Testing expands to thousands of patients across international clinical centers. The objective is to statistically confirm the treatment’s efficacy compared to existing standards of care and to monitor adverse effects over longer periods.
- Phase 4 (Post-Marketing Surveillance): Occurring after formal drug approval, this phase involves continuous monitoring to evaluate the long-term results, interactions, and overall safety of the molecule in the general population.
Complexities in the Field of Rare Diseases
Conducting clinical trials for rare pathologies presents unique structural hurdles. It is estimated that only 5% of rare diseases currently have a dedicated therapy. The main challenges include:
- Patient Dispersion: The small number of patients makes it statistically complex to reach the large cohorts required for a traditional Phase 3 trial. Furthermore, forming homogeneous study groups to compare coherent data is highly challenging.
- Funding and Incentives: The high cost of research can deter investments due to the small population sizes. To address this, specific “orphan drug” legislations provide economic incentives, accelerated approval pathways, and patent extensions to encourage collaborative therapeutic development in these sectors.
Specific Hurdles for Charcot-Marie-Tooth (CMT)
In addition to the challenges shared by all rare diseases, Charcot-Marie-Tooth requires researchers to overcome two distinct biological and clinical barriers:
- Slow Clinical Progression and the Need for Biomarkers: CMT symptoms develop and progress very gradually over decades. In a standard clinical trial lasting one to three years, clinical variations can be imperceptible, making it difficult to measure a drug’s efficacy. To solve this, the scientific community is actively working to identify highly sensitive biomarkers, such as advanced quantitative muscle MRI, capable of detecting microscopic improvements or the slowing of degeneration in short timeframes.
- The Blood-Nerve Barrier: For a treatment to be effective for CMT, it must reach the cells of the peripheral nerves. The peripheral nervous system is protected by a dense barrier (the blood-nerve barrier) that prevents the indiscriminate entry of external molecules. Engineering a drug that is both effective and capable of crossing this selective membrane intact is currently one of the foremost pharmacological challenges.
Source and Further Information:
